229 related articles for article (PubMed ID: 23551065)
21. Current management of breakthrough cancer pain according to physicians from pain units in Spain.
Estévez FV; Alarcón MDL; Mayoral V; de Madariaga M; Margarit C; Duran JA; Martín-Arroyo JMT; Carregal A;
Clin Transl Oncol; 2019 Sep; 21(9):1168-1176. PubMed ID: 30783918
[TBL] [Abstract][Full Text] [Related]
22. Breakthrough Cancer Pain in Patients With Abdominal Visceral Cancer Pain.
Mercadante S; Adile C; Masedu F; Valenti M; Aielli F
J Pain Symptom Manage; 2019 May; 57(5):966-970. PubMed ID: 30822530
[TBL] [Abstract][Full Text] [Related]
23. Breakthrough pain in patients with head & neck cancer. A secondary analysis of IOPS MS study.
Mercadante S; Masedu F; Valenti M; Aielli F
Oral Oncol; 2019 Aug; 95():87-90. PubMed ID: 31345399
[TBL] [Abstract][Full Text] [Related]
24. How nurses assess breakthrough cancer pain, and the impact of this pain on patients' daily lives--results of a European survey.
Rustøen T; Geerling JI; Pappa T; Rundström C; Weisse I; Williams SC; Zavratnik B; Wengström Y
Eur J Oncol Nurs; 2013 Aug; 17(4):402-7. PubMed ID: 23276599
[TBL] [Abstract][Full Text] [Related]
25. Breakthrough pain in patients with multiple myeloma: a secondary analysis of IOPS MS study.
Mercadante S; Caraceni A; Cuomo A; Mammucari M; Marchetti P; Mediati RD; Natoli S; Tonini G
Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):1134-1139. PubMed ID: 36808361
[TBL] [Abstract][Full Text] [Related]
26. Breakthrough Cancer Pain Influences General Activities and Pain Management: A Comparison of Patients with and without Breakthrough Cancer Pain.
Tagami K; Okizaki A; Miura T; Watanabe YS; Matsumoto Y; Morita T; Fujimori M; Kinoshita H
J Palliat Med; 2018 Nov; 21(11):1636-1640. PubMed ID: 29975582
[TBL] [Abstract][Full Text] [Related]
27. What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion.
; Vellucci R; Fanelli G; Pannuti R; Peruselli C; Adamo S; Alongi G; Amato F; Consoletti L; Lamarca L; Liguori S; Lo Presti C; Maione A; Mameli S; Marinangeli F; Marulli S; Minotti V; Miotti D; Montanari L; Moruzzi G; Palermo S; Parolini M; Poli P; Tirelli W; Valle A; Romualdi P
Drugs; 2016 Mar; 76(3):315-30. PubMed ID: 26755179
[TBL] [Abstract][Full Text] [Related]
28. Breakthrough cancer pain (BTcP): a synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy.
Zucco F; Bonezzi C; Fornasari D
Adv Ther; 2014 Jul; 31(7):657-82. PubMed ID: 25005168
[TBL] [Abstract][Full Text] [Related]
29. Treating breakthrough pain in oncology.
Mercadante S
Expert Rev Anticancer Ther; 2018 May; 18(5):445-449. PubMed ID: 29478355
[TBL] [Abstract][Full Text] [Related]
30. Breakthrough Cancer Pain: A Systematic Review of Pharmacologic Management
.
Brant JM; Rodgers BB; Gallagher E; Sundaramurthi T
Clin J Oncol Nurs; 2017 Jun; 21(3 Suppl):71-80. PubMed ID: 28524907
[TBL] [Abstract][Full Text] [Related]
31. Breakthrough cancer pain treatment in Spain: physicians' perception of current opioids utilization and prescription.
Villegas Estévez F; López Alarcón MD; Alonso Babarro A; Olay Gayoso L; de Castro J; Lería-Gelabert M; Melogno-Klinkas M
Curr Med Res Opin; 2020 Aug; 36(8):1383-1391. PubMed ID: 32453602
[No Abstract] [Full Text] [Related]
32. Intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
Dietrich E; Gums JG
Ann Pharmacother; 2012 Oct; 46(10):1382-91. PubMed ID: 23012382
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment.
Cortesi PA; D'Angiolella LS; Vellucci R; Allegri M; Casale G; Favaretti C; Kheiraoui F; Cesana G; Mantovani LG
PLoS One; 2017; 12(6):e0179523. PubMed ID: 28654672
[TBL] [Abstract][Full Text] [Related]
34. Breakthrough cancer pain and rational drug use.
Olarte JM
Support Care Cancer; 2017 Apr; 25(Suppl 1):11-17. PubMed ID: 28213817
[TBL] [Abstract][Full Text] [Related]
35. Increased quality of life in patients with breakthrough cancer pain after individualized therapy: the CAVIDIOM study.
Villarroel PG; Padró JG; Marquina G; Jáñez NM; González EE; Antón A; Sánchez MB; Cáceres AR; López-López R; Cornejo RE; García PB; Fabregat RM; Fernández BC; Bermudo CL; Camps C
Future Oncol; 2022 Nov; 18(35):3913-3927. PubMed ID: 36537885
[TBL] [Abstract][Full Text] [Related]
36. Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain.
Überall MA; Müller-Schwefe GH
Curr Med Res Opin; 2011 Jul; 27(7):1385-94. PubMed ID: 21561313
[TBL] [Abstract][Full Text] [Related]
37. Pain characteristics and management of inpatients admitted to a comprehensive cancer centre: a cross-sectional study.
Kurita GP; Tange UB; Farholt H; Sonne NM; Strömgren AS; Ankersen L; Kristensen L; Bendixen L; Grønvold M; Petersen MA; Nordly M; Christrup L; Niemann C; Sjøgren P
Acta Anaesthesiol Scand; 2013 Apr; 57(4):518-25. PubMed ID: 23336265
[TBL] [Abstract][Full Text] [Related]
38. Breakthrough pain in patients referred to pain clinics: the Italian pain network retrospective study.
Gatti A; Mediati RD; Reale C; Cuomo A; Vellucci R; Russo G; Costantini A; Canneti A; Luzi M; Mammucari M; Sabato AF
Adv Ther; 2012 May; 29(5):464-72. PubMed ID: 22622488
[TBL] [Abstract][Full Text] [Related]
39. Fentanyl citrate sublingual formulation (Vellofent®) for quick BTcP hindering.
Romualdi P; Candeletti S
Minerva Med; 2016 Apr; 107(2):114-22. PubMed ID: 27064584
[TBL] [Abstract][Full Text] [Related]
40. The use of opioids for breakthrough pain in acute palliative care unit by using doses proportional to opioid basal regimen.
Mercadante S; Villari P; Ferrera P; Mangione S; Casuccio A
Clin J Pain; 2010 May; 26(4):306-9. PubMed ID: 20393265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
